Join the club for FREE to access the whole archive and other member benefits.

Achilles raised $175.5 million to develop new cancer immunotherapies


Key points from article :

Cancer Research UK’s spinout, Achilles, raised $175.5 million to invest in the development of new cancer immunotherapies.

Cancer immunotherapies developed by Achilles are based on fundamental discoveries of how cancers develop and evolve.

Uses principles of tumour evolution to wind back the clock and pick out mutations that arose at the very early stages of cancer.

This allows to identify neoantigens present on all cancer cells within a tumour, known as clonal tumour neoantigens.

“We formed Achilles with Syncona to drive revolution in cancer treatment using clonal neoantigens to develop personalised T cell therapies,” - Tony Hickson, chief business officer for Cancer Research UK.

Two ongoing Phase 1/2a trials, including testing an patients with advanced non-small cell lung cancer and malignant melanoma that's come back or spread to other parts of the body.

Entered the world’s second largest stock market, NASDAQ, and is a strong indicator of the companies growing success.

Patient-specific cell therapies under clinical trials for treating lung cancer and melanoma

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Biopharmaceutical company developing personalized cancer immunotherapies


Independent cancer charity focused on saving lives through research, influence and information

Company Representative

Chief Business Officer at Cancer Research UK